Home - Genedrive

Transforming patient outcomes through rapid
pharmacogenetic testing

Empowering clinicians to deliver rapid, personalised medicine

Transforming patient outcomes through rapid
pharmacogenetic testing

MT-RNR1

Improving patient outcomes with personalised antibiotic treatment

Find out more

CYP2C19

Improving patient outcomes with personalised antiplatelet treatment

Find out more

Genedrive® System

 Molecular diagnostic platform

Find out more

MT-RNR1

Personalised antibiotic treatment

Find out more

CYP2C19

 Personalised cardiovascular treatment

Find out more

Company Overview

Genedrive Diagnostics Ltd is a pharmacogenetic testing company developing and commercialising a rapid and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. Based in the UK, the Company is at the forefront of Point of Care pharmacogenetic testing in emergency healthcare.

Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both developed and validated in collaboration with NHS partners.

Find out more

The implementation of the Genedrive MT-RNR1 test across all neonatal sites in Greater Manchester represents a significant advancement in preventing hearing loss in infants and enabling rapid genetic testing at the bedside.

Dr Ajit Mahaveer

Clinical Lead for the Northwest Neonatal Operational Delivery Network (NWNODN)

Manchester’s ground-breaking bedside test for detecting whether an antibiotic could cause deafness in babies in intensive care is another example of how the NHS is harnessing the power of genomic medicine to transform patient care.

Professor Dame Sue Hill

Chief Scientific Officer for England and Senior Responsible Officer for Genomics in the NHS

Having this test available nationally will ensure no baby will go deaf unnecessarily.

Dr John McDermott

Clinical Geneticist at Manchester University NHS Foundation Trust

The development of this new point-of-care diagnostic has the potential to significantly improve care for tens of thousands of patients after a stroke.

Professor William Newman

Professor of Translational Genomic Medicine at the University of Manchester and Lead of the NHSE Network of Excellence in Pharmacogenetics and Medicines Optimisation at Manchester University NHS Foundation Trust

Health Innovation Manchester is pleased to continue to work with genedrive and our academic and health partners to ensure the sustained deployment of this innovative test across the whole of Greater Manchester.

Jonathan Massey

Programme Director for Academia at Health Innovation Manchester

We are delighted to bring the benefit of this novel technology to Stroke patients in our region. Effective clinical management of neurologic stroke relies in part on optimising the efficacy of anti-platelets prescribed, and within a timeframe that is served only by rapid genetic testing technologies such as this. The implementation will help us to formulate a personalised optimal treatment plan for our stroke patients, that we hope will prevent future strokes and save lives.

Professor Radim Licenik

Consultant Stroke Physician, Clinical Lead for Stroke Service and President of the Society of Czech & Slovak Doctors in the UK

trusted by

21 Aug 2025 PR

Scotlands Public Health Minister Visit

14 Aug 2025 PR

Comment re: Share Price Movement

Latest Events

View all

16 Oct 2025 England

HSJ Medicines Forum

22 Oct 2025 Europe

World Stroke Congress

04 Nov 2025 UK

POCT-For-Scot